We are live on ! Find out more
CRBU icon

Caribou Biosciences

140 hedge funds and large institutions have $87.6M invested in Caribou Biosciences in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 41 increasing their positions, 43 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 43

7% less funds holding

Funds holding: 151140 (-11)

15.05% less ownership

Funds ownership: 73.91%58.86% (-15%)

25% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 36

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

67% less call options, than puts

Call options by funds: $54K | Put options by funds: $163K

74% less capital invested

Capital invested by funds: $343M → $87.6M (-$255M)

Holders
140
Holders Change
-11
Holders Change %
-7.28%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
27
Increased
41
Reduced
43
Closed
36
Calls
$54K
Puts
$163K
Net Calls
-$109K
Net Calls Change
-$182K
Name Holding Trade Value Shares
Change
Change in
Stake
RJA
51
Raymond James & Associates
Florida
$151K -$29K -9,078 -9%
NCM
52
Nelson Capital Management
California
$139K
HSBC Holdings
53
HSBC Holdings
United Kingdom
$129K +$214K +66,838 +476%
GAA
54
Green Alpha Advisors
Colorado
$127K -$19.7K -6,150 -7%
BHCM
55
Brevan Howard Capital Management
Jersey
$126K +$214K +66,867 +652%
Squarepoint
56
Squarepoint
New York
$113K -$324K -101,325 -60%
Invesco
57
Invesco
Georgia
$110K -$9.79K -3,062 -4%
Susquehanna International Group
58
Susquehanna International Group
Pennsylvania
$104K -$116K -36,404 -36%
Citadel Advisors
59
Citadel Advisors
Florida
$102K -$1.48M -464,424 -88%
Barclays
60
Barclays
United Kingdom
$95.7K -$124K -38,857 -40%
Commonwealth Equity Services
61
Commonwealth Equity Services
Massachusetts
$92K +$21.2K +6,621 +13%
Citigroup
62
Citigroup
New York
$86.2K -$1.33M -416,929 -89%
Balyasny Asset Management
63
Balyasny Asset Management
Illinois
$86K -$352K -110,264 -68%
MIM
64
MetLife Investment Management
New Jersey
$80K +$25.8K +8,069 +20%
BWP
65
Balboa Wealth Partners
Arizona
$78.5K +$153K +47,876 New
CF
66
Corebridge Financial
Texas
$72.6K +$141K +44,261 New
Royal Bank of Canada
67
Royal Bank of Canada
Ontario, Canada
$71K +$12.9K +4,052 +10%
Wells Fargo
68
Wells Fargo
California
$68.2K +$20.2K +6,306 +18%
ETC
69
Exchange Traded Concepts
Oklahoma
$66.5K -$40.3K -12,614 -24%
PFCS
70
Pale Fire Capital SE
Czech Republic
$64.1K +$55.6K +17,407 +80%
TRCT
71
Tower Research Capital (TRC)
New York
$64.1K +$111K +34,674 +783%
Manulife (Manufacturers Life Insurance)
72
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$59.8K +$16.8K +5,244 +17%
CIC
73
Cornercap Investment Counsel
Georgia
$57.9K -$1.44K -449 -1%
New York State Common Retirement Fund
74
New York State Common Retirement Fund
New York
$56.3K +$243 +76 +0.2%
Envestnet Asset Management
75
Envestnet Asset Management
Illinois
$54.4K +$106K +33,148 New

CRBU Hedge Fund Activity: Q2 2024 in Review

140 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q2 2024, worth a combined $87.6M — down 74% from $343M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of CRBU and 27 opened new positions — a net loss of 9 holders — while 43 trimmed existing stakes and 41 added.

The largest buyer was Bank of America, adding an estimated $9.73M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $29.7M sold.

  • 140 institutional investors held Caribou Biosciences (CRBU) as of Q2 2024, down from 151 in Q1 2024.
  • Funds reported $87.6M of Caribou Biosciences stock for Q2 2024, down 74% quarter-over-quarter.
  • 27 funds opened new Caribou Biosciences positions in Q2 2024 and 36 closed out, a net change of -9 holders.
  • The largest Caribou Biosciences buyer in Q2 2024 was Bank of America, an estimated $9.73M added.
  • The largest Caribou Biosciences seller in Q2 2024 was Avidity Partners Management, an estimated $29.7M sold.

Based on aggregated 13F filings for Q2 2024.